ARCA Biopharma Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $31.56 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
ARCA Biopharma Inc had its IPO on 1997-08-08 under the ticker symbol ABIO.
The company operates in the Healthcare sector and Biotechnology industry. ARCA Biopharma Inc has a staff strength of 5 employees.
Shares of ARCA Biopharma Inc opened at $2 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $2 - $2.05, and closed at $2.01.
This is a 0% increase from the previous day's closing price.
A total volume of 28,470 shares were traded at the close of the day’s session.
In the last one week, shares of ARCA Biopharma Inc have slipped by -1.95%.
ARCA Biopharma Inc's Key Ratios
ARCA Biopharma Inc has a market cap of $31.56 million, indicating a price to book ratio of 0.769 and a price to sales ratio of 0.
In the last 12-months ARCA Biopharma Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-9821000. The EBITDA ratio measures ARCA Biopharma Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, ARCA Biopharma Inc’s operating margin was 0% while its return on assets stood at -12.55% with a return of equity of -21.41%.
In Q4, ARCA Biopharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
ARCA Biopharma Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.68 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ARCA Biopharma Inc’s profitability.
ARCA Biopharma Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.7385. Its price to sales ratio in the trailing 12-months stood at 0.
ARCA Biopharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $43.09 million
- Total Liabilities
- $1.13 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
ARCA Biopharma Inc ended 2023 with $43.09 million in total assets and $0 in total liabilities. Its intangible assets were valued at $43.09 million while shareholder equity stood at $41.67 million.
ARCA Biopharma Inc ended 2023 with $0 in deferred long-term liabilities, $1.13 million in other current liabilities, 14000.00 in common stock, $-183402000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $42.45 million and cash and short-term investments were $42.45 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
ARCA Biopharma Inc’s total current assets stands at $42.70 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $334000.00 and inventory worth $0.
In 2023, ARCA Biopharma Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, ARCA Biopharma Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
ARCA Biopharma Inc stock is currently trading at $2.01 per share. It touched a 52-week high of $2.7 and a 52-week low of $2.7. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $2.15 and 200-day moving average was $2.24 The short ratio stood at 9.07 indicating a short percent outstanding of 0%.
Around 102.1% of the company’s stock are held by insiders while 4591.4% are held by institutions.
Frequently Asked Questions About ARCA Biopharma Inc
Similar Industry Stocks (Biotechnology)
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado’s Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.